Compare VRME & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | CANF |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | Israel |
| Employees | 41 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 4.7M |
| IPO Year | N/A | 2011 |
| Metric | VRME | CANF |
|---|---|---|
| Price | $0.88 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.50 | ★ $9,750.00 |
| AVG Volume (30 Days) | 165.7K | ★ 609.7K |
| Earning Date | 03-06-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | $290,391.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.17 |
| 52 Week High | $1.51 | $10.40 |
| Indicator | VRME | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 35.75 |
| Support Level | $0.81 | $0.60 |
| Resistance Level | $0.97 | $4.74 |
| Average True Range (ATR) | 0.08 | 0.64 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 13.82 | 0.90 |
VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.